JULIO BELARMINO
BOBES GARCIA
Investigador hasta 2022
![Foto de JULIO BELARMINO](/img/nophoto.png)
![Foto de Hospital Ramón y Cajal](/img/noimage_org.png)
Hospital Ramón y Cajal
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (29)
2021
-
Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis
Schizophrenia Research, Vol. 236, pp. 19-28
-
The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis
Psychopharmacology, Vol. 238, Núm. 3, pp. 665-676
2020
-
Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study
Schizophrenia Research, Vol. 218, pp. 292-294
-
Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis
Psychological Medicine, Vol. 50, Núm. 16, pp. 2702-2710
-
Suicide. The post-COVID era: A time for action
Revista de Psiquiatria y Salud Mental
2019
-
Barriers to complete recovery of major depression: cross-sectional, multi-centre study on clinical practice. RECORD study
Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 3, pp. 141-150
-
Patient characteristics driving clinical utility in psychiatric pharmacogenetics: a reanalysis from the AB-GEN multicentric trial
Journal of Neural Transmission, Vol. 126, Núm. 1, pp. 95-99
-
Pharmacological treatment of obsessive compulsive disorder in adults: A clinical practice guideline based on the ADAPTE methodology
Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 2, pp. 77-91
2018
-
Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis
Schizophrenia Research, Vol. 193, pp. 188-196
-
Factors associated with poor functional outcome in bipolar disorder: sociodemographic, clinical, and neurocognitive variables
Acta Psychiatrica Scandinavica, Vol. 138, Núm. 2, pp. 145-154
-
Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?
Psychological Medicine, Vol. 48, Núm. 13, pp. 2247-2256
2017
-
Do patients with bipolar disorder and subsyndromal symptoms benefit from functional remediation? A 12-month follow-up study
European Neuropsychopharmacology, Vol. 27, Núm. 4, pp. 350-359
-
Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: Results of a randomized, double-blind clinical trial
BMC Psychiatry, Vol. 17, Núm. 1
-
The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study
Schizophrenia Research, Vol. 189, pp. 84-90
2016
-
Antipsychotic switching in schizoaffective disorder: A systematic review
World Journal of Biological Psychiatry, Vol. 17, Núm. 7, pp. 495-513
-
Cognitive reserve in bipolar disorder: Relation to cognition, psychosocial functioning and quality of life
Acta Psychiatrica Scandinavica, Vol. 133, Núm. 5, pp. 386-398
-
Effects of functional remediation on neurocognitively impaired bipolar patients: Enhancement of verbal memory
Psychological Medicine, Vol. 46, Núm. 2, pp. 291-301
-
Functional remediation in bipolar disorder: 1-year follow-up of neurocognitive and functional outcome
British Journal of Psychiatry, Vol. 208, Núm. 1, pp. 87-93
2014
-
Antipsychotic switching in bipolar disorders: A systematic review
International Journal of Neuropsychopharmacology, Vol. 17, Núm. 3, pp. 497-507
-
Consenso español de salud física del paciente con depresión
Revista de Psiquiatria y Salud Mental, Vol. 7, Núm. 4, pp. 195-207